Nonalcoholic Fatty Liver Disease As a Risk Factor for Clostridioides Difficile Infection
Overview
Microbiology
Affiliations
Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea while nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The aim of this study was to determine whether NAFLD increases susceptibility to CDI. A retrospective cohort study included patients ≥ 65 years, treated with antimicrobial therapy ≥ 24 h, and hospitalized ≥ 72 h in a 36-month period. Three-hundred fourteen patients were included; 83 with NAFLD and 231 controls. Except for diabetes mellitus (37.35% vs. 25.11%, p = 0.0462) and obesity (18.07% vs. 8.23%, p = 0.0218) that were more frequent in NAFLD group, there were no differences in other comorbidities, hospital admissions, antibiotic therapy within 3 months, prescription, and duration of antibiotic therapy. Fourteen (16.9%) patients with NAFLD and 17 (7.4%) in control group developed in-hospital CDI (p = 0.0156). The Charlson Age-Comorbidity Index > 6 (OR 4.34, 95%CI 1.39-13.57), hospital admission within 3 months (OR 7.14, 95%CI 2.33-21.83), serum albumins < 28 g/L (OR 3.15, 95%CI 1.04-9.53), NAFLD (OR 3.27, 95%CI 1.04-10.35), eGFR < 40 (OR 4.89, 95%CI 1.61-14.88), treatment with piperacillin/tazobactam (OR 4.86, 95%CI 1.59-14.83), and carbapenems (OR 3.99, 95%CI 1.28-12.40) were independently associated with CDI. Our study identified NAFLD as an independent predictor of CDI.
The Impact of Steatotic Liver Disease on Cytokine and Chemokine Kinetics During Sepsis.
Vrsaljko N, Radmanic Matotek L, Zidovec-Lepej S, Vince A, Papic N Int J Mol Sci. 2025; 26(5).
PMID: 40076848 PMC: 11900930. DOI: 10.3390/ijms26052226.
Lee E, Kim J, Yoon S J Clin Med. 2025; 14(2).
PMID: 39860549 PMC: 11765748. DOI: 10.3390/jcm14020542.
Mantovani A, Morandin R, Fiorio V, Lando M, Gaviraghi A, Motta L Liver Int. 2024; 45(4):e16101.
PMID: 39258758 PMC: 11892334. DOI: 10.1111/liv.16101.
Steatotic Liver Disease and Sepsis Outcomes-A Prospective Cohort Study (SepsisFAT).
Krznaric J, Papic N, Vrsaljko N, Gjurasin B, Kutlesa M, Vince A J Clin Med. 2024; 13(3).
PMID: 38337491 PMC: 10856507. DOI: 10.3390/jcm13030798.
infection in patients with nonalcoholic fatty liver disease-current status.
Kiseleva Y, Maslennikov R, Gadzhiakhmedova A, Zharikova T, Kalinin D, Zharikov Y World J Hepatol. 2023; 15(2):208-215.
PMID: 36926243 PMC: 10011916. DOI: 10.4254/wjh.v15.i2.208.